Britain's National Institute for Health and Care Excellence (NICE) rejected Novartis’s migraine drug, Aimovig, concluding that the drug was not a cost-effective use of resources.
While NICE found that the drug demonstrated clinical effectiveness, the agency concluded there was not enough evidence to suggest it is more effective than Allergan's Botox. NICE also raised questions about long-term effectiveness.
The decision comes just months after the price watchdog declined to endorse Novartis' cell therapy, Kymriah, in adult lymphoma patients.
Read the Reuters coverage